心脏主动脉瓣狭窄疾病，重点在高危老年心脏主动脉瓣狭窄疾病的腔内微创治疗为学术突破方向；

动脉扩张性疾病，重点在主动脉夹层和主动脉瘤，以升主动脉、主动脉弓及复杂性主动脉疾病的腔内微创治疗为学术突破方向；

下肢动脉阻塞性疾病，重点在髂、股、腘、小腿及足部动脉闭塞，以长段难治性下肢动脉闭塞及远端难治性细小动脉闭塞腔内微创治疗为学术突破方向；

颈动脉阻塞性疾病，重点在颅外颈动脉狭窄及闭塞，以颈动脉难治性及高风险性完全闭塞的腔内微创及杂交治疗为学术突破方向。

Aortic Stenosis in Elderly High-Risk Patients: Focusing on transcatheter aortic valve replacement (TAVR) and other endovascular minimally invasive treatments for severe aortic stenosis. This approach is particularly significant for elderly patients who may not be suitable candidates for open-heart surgery due to comorbidities and advanced age.

Aortic Aneurysms and Dissections: Concentrating on endovascular aneurysm repair (EVAR) and other minimally invasive techniques for the treatment of ascending aorta, aortic arch, and complex aortic diseases. This includes the management of aortic dissections and aneurysms in high-risk patients, aiming to reduce the invasiveness and risks associated with traditional open surgeries.

Peripheral Arterial Occlusive Diseases: Targeting the endovascular treatment of long-segment and distal occlusions in the iliac, femoral, popliteal, and lower leg arteries. This involves addressing difficult-to-treat occlusions in the lower extremities, including the foot, using advanced minimally invasive techniques to restore blood flow and prevent amputations.

Carotid Artery Occlusive Diseases: Emphasizing the endovascular and hybrid treatments for challenging and high-risk cases of carotid artery stenosis and occlusion, particularly involving the extracranial portion. This includes the development of innovative approaches to manage complete carotid artery occlusions in patients at high surgical risk, aiming to reduce stroke risk and improve outcomes.

1、同济大学附属上海第四人民医院血管病中心主任

2、同济大学医学院教授、博士生导师

3、同济大学附属上海第四人民医院院士培养对象

4、同济大学附属上海第四人民医院主任医师

5、同济大学附属上海第四人民医院外科教研室名誉主任

6、同济大学附属上海第四人民医院临床研究中心名誉主任

7、上海市血管系统疾病临床医学中心主任

8、中国医师协会腔内血管学专业委员会名誉主任委员

1、Director of the Vascular Disease Center at Shanghai No.4 People’s Hospital Affiliated to Tongji University

2、Professor and Doctoral Supervisor at the College of Medicine, Tongji University

3、Candidate for Academician at Shanghai No.4 People’s Hospital Affiliated to Tongji University

4、Chief Physician at Shanghai No.4 People’s Hospital Affiliated to Tongji University

5、Honorary Director of the Department of Surgical Education at Shanghai No.4 People’s Hospital Affiliated to Tongji University

6、Honorary Director of the Clinical Research Center at Shanghai No.4 People’s Hospital Affiliated to Tongji University

7、Director of the Shanghai Clinical Medicine Center for Vascular System Diseases

8、Honorary Chairman of the Endovascular Committee of the Chinese Medical Association

景在平，中国医师协会腔内血管学专业委员会主任委员，从事血管外科医教研工作，是中国主动脉疾病腔内微创治疗领域的开拓者，原创研发并转化国际先进水平的新器具和适配技术，创建以“腔内血管学ENDOVASCOLOGY”为核心的全新理论体系，显著提升严重影响人民生命健康的危重血管病的救治水平，带动我国主动脉扩张病微创治疗跻身国际先进行列。主持国家863项目、国家科技攻关项目、国家自然科学基金重点项目等35项；以通讯作者发表SCI论文86篇，总影响因子283.7（单篇最高19.9），总被引591次；主编国际、国内专著9部；获国家专利授权95项（发明专利25项）；以第一完成人获国家科技进步二等奖、教育部科技进步一等奖、中华医学科技奖一等奖、军队医疗成果一等奖等，牵头组建国家级教学团队，获国家教学成果二等奖、军队教学成果一等奖及全军育才金奖等，享国务院特殊津贴，荣立个人二等功、个人三等功各1次，获中央保健委“保健工作特别贡献奖”等奖励。

Jing Zai Ping, the chairman of the Endovascular Committee of the Chinese Medical Association, is dedicated to medical, teaching, and research work in vascular surgery. He is a pioneer in the field of endovascular minimally invasive treatment for aortic diseases in China. Jing has innovatively developed and transformed new instruments and adaptive technologies to international advanced levels. He established a new theoretical system centered on "Endovasculology," significantly improving the treatment level of severe vascular diseases that greatly impact the public health. His work has propelled China’s minimally invasive treatment for aortic dilation diseases to the forefront internationally.

Jing has led 35 projects, including those funded by the National 863 Program, National Science and Technology Key Projects, and the National Natural Science Foundation’s Key Projects. As the corresponding author, he has published 86 SCI-indexed papers with a total impact factor of 283.7 (highest single paper impact factor of 19.9), and these papers have been cited a total of 591 times. He has edited nine professional books both internationally and domestically. Jing has been granted 95 national patents (including 25 invention patents). As the lead researcher, he has received the Second-Class National Science and Technology Progress Award, the First-Class Science and Technology Progress Award of the Ministry of Education, the First-Class Chinese Medical Science and Technology Award, and the First-Class Medical Achievement Award of the PLA, among others.

He has led the establishment of a national-level teaching team and has received the Second-Class National Teaching Achievement Award, the First-Class Teaching Achievement Award of the PLA, and the Gold Medal for Talent Cultivation of the PLA, among other honors. He is entitled to special allowances from the State Council. He has been commended with a Second-Class Personal Merit and a Third-Class Personal Merit, and received the "Special Contribution Award for Health Care" from the Central Health Care Commission, among other recognitions.

Jing’s contributions have significantly enhanced the medical field’s ability to treat vascular diseases in China, demonstrating his dedication to improving public health and advancing medical science.